NasdaqCM - Nasdaq Real Time Price
USD
Unicycive Therapeutics, Inc. (UNCY)
3.7400
-0.0700
(-1.84%)
At close: October 30 at 4:00:00 PM EDT
3.2000
-0.5400
(-14.44%)
After hours: October 30 at 7:59:39 PM EDT
Trade UNCY on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for UNCY
What's happening with UNCY?
Powered by Yahoo ScoutUnicycive Therapeutics received FDA acceptance for its resubmitted application for oxylanthanum carbonate, with a March 25, 2027 PDUFA date. The acceptance advances the review, but manufacturing inspections remain a key approval risk. UNCY’s latest regular-session move was down 1.84%as of November 1, 2026.
Powered by Yahoo Scout
- Previous Close
3.8100 - Open
3.7700 - Bid 3.7000 x 200
- Ask 3.7000 x 100
- Day's Range
3.6225 - 3.9300 - 52 Week Range
3.3500 - 8.7400 - Volume
977,989 - Avg. Volume
897,682 - Market Cap (intraday)
102.45M - Beta (5Y Monthly) 1.82
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7200 - Earnings Date (est.) Nov 12, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
28.40 - Zacks Rating Neutral
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
UNCY
35.18%
S&P 500 (^GSPC)
10.73%
1-Year Return
UNCY
22.25%
S&P 500 (^GSPC)
11.11%
3-Year Return
UNCY
38.89%
S&P 500 (^GSPC)
81.91%
5-Year Return
UNCY
87.06%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/30/2026
-
Market Cap
104.18M
-
Enterprise Value
43.49M
-
Trailing P/E
--
-
Forward P/E
2.07
-
PEG Ratio (current)
--
-
Price/Sales (ttm)
--
-
Price/Book (mrq)
1.96
-
Enterprise Value/Revenue
--
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-40.59%
-
Return on Equity (ttm)
-101.07%
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
-35.22M
-
Diluted EPS (ttm)
-1.7200
Balance Sheet and Cash Flow
-
Total Cash (mrq)
61.42M
-
Total Debt/Equity (mrq)
1.26%
-
Levered Free Cash Flow (ttm)
-12.72M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
